Avelumab Survey

The purpose of this survey is to provide the Canadian Cancer Survivor Network (CCSN) with insights and perspectives about the use of Avelumab for the treatment of patients with Merkel cell carcinoma. The survey will be open until Oct. 20.

The results of our survey are to be submitted in our patient evidence study to the pan-Canadian Oncology Drug Review (pCODR) on Oct. 24, 2017.

To complete the survey, please click here.